16 RESULTS
Go to another page:
COMMENT I am pleased to hear the positive news on donanemab and agree that it is likely to be approved soon. Donanemab has some potential advantages over lecanemab, but also may have some weaknesses, so it will be nice for clinicians to have both as options. Cert
COMMENT This is an exciting finding. It builds on work from Hugo Bellen’s lab, which showed that astrocytes can take up lipid droplets from stressed/injured neurons as a neuroprotective mechanism. This new paper provides a novel connection to sleep deprivation, w
COMMENT The top-line results from Lilly today are very exciting to me for several reasons. First, these data really strengthen the argument that plaque removal has a meaningful clinical effect in mildly symptomatic patients. With Phase 1b/2 trials for aducanumab,
COMMENT I must commend these investigators for integrating plasma AD biomarkers into their study of a behavioral intervention. That they saw changes in these biomarkers with this relatively mild intervention is quite interesting and exciting. Interpreting those c
COMMENT I’m cautiously optimistic about the lecanemab data. Because there is such mild decline in these patients over 18 months, it’s very difficult to see a positive signal, particularly when it takes several months to titrate the medication and remove the plaqu
COMMENT These results are very exciting, though we all, of course, need to see the actual data before drawing any major conclusions. I think that the incomplete trials for aducanumab left the field at a tipping point: On one hand, the Phase 1b/2 trials for aducan
COMMENT I don’t think this coverage decision changes much. Practically, it’s a denial of coverage. I don’t know of any trials that would qualify for CMS support under these criteria that are not being run by Biogen (and thus already have free drug). Perhaps some
COMMENT To me, the logic behind this proposed NCD is confusing. No one besides Biogen is likely to have the incentive or money to run another sufficiently large, randomized, placebo-controlled Phase 3 study of aducanumab. And Biogen is already doing this. Now, it
COMMENT Morawska et al. have expanded upon previous studies showing that sleep enhancement/deprivation can influence Aβ and tau deposition to now show that the same holds true for α-synuclein. They have taken care to characterize the effects of sodium oxybate on
COMMENT In this very interesting paper, Jagirdar et al. demonstrate both fragmented sleep and hyperactivity of the thalamic reticular nucleus in J20 APP transgenic mice. They use DREDDS to alter neuronal activity in this nucleus, thereby increasing slow-wave slee
COMMENT This nice study is consistent with several smaller previous studies linking self-reported sleep issues (in this case, short sleep duration) with brain amyloid level as assessed by amyloid PET. This study has a very large number of people with amyloid PET
COMMENT Regardless of one’s opinion on the drug, the Aduhelm approval is likely to have a huge impact on research and clinical practice. Regarding clinical practice, I was very surprised by the broad indication from the FDA. It seems to fly in the face of all exi
COMMENT The Phase 2 data on donanemab is encouraging and raises expectations for Phase 3 trials. The effect size on the primary endpoint (iADRS score) is considerable and very promising. However, secondary endpoints such as CDR-SB, ADAS-Cog13, and MMSE were less
COMMENT This is an exciting paper, which provides a possible mechanistic link between slow-wave neuronal activity during NREM sleep and pulsations in CSF flow. It offers a new insight into how sleep-related changes in neuronal activity potentially alter CSF dynam
COMMENT This is an interesting paper, and I think it is well-conducted and meaningful. An important takeaway is that circadian regulation of cellular function is complex, and the effects of clock disruption on measures of disease may be highly context-dependent.
Go to another page:
